| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.87▲ | 2.86▲ | 2.85▲ | 2.77▲ | 2.80▲ |
| MA10 | 2.87▲ | 2.84▲ | 2.78▲ | 2.85▲ | 2.80▲ |
| MA20 | 2.86▲ | 2.76▲ | 2.68▲ | 2.79▲ | 2.27▲ |
| MA50 | 2.84▲ | 2.72▲ | 2.81▲ | 2.72▲ | 1.85▲ |
| MA100 | 2.78▲ | 2.81▲ | 2.81▲ | 2.12▲ | 2.06▲ |
| MA200 | 2.68▲ | 2.81▲ | 2.79▲ | 1.72▲ | 3.13▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.014▲ | 0.037▲ | -0.020▼ | 0.040▲ |
| RSI | 63.856▲ | 64.482▲ | 60.566▲ | 53.600▲ | 60.785▲ |
| STOCH | 60.859 | 81.652▲ | 90.527▲ | 48.480 | 49.066 |
| WILL %R | -18.182▲ | -3.704▲ | -2.532▲ | -32.047 | -31.548 |
| CCI | 166.528▲ | 104.131▲ | 96.938 | 0.684 | 56.711 |
|
Monday, November 10, 2025 05:06 AM
Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% ...
|
|
Monday, November 10, 2025 03:25 AM
Esperion Therapeutics stock remains a buy as strong drug franchises, growth, and global milestones outweigh risks. Learn more about ESPR stock now.
|
|
Friday, November 07, 2025 05:32 AM
Q3 2025 Earnings Call Transcript November 6, 2025 Esperion Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.15812 EPS, expectations were $-0.09. Operator: Hello, ladies and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 10/11/25 | 2.69 | 2.90 | 2.65 | 2.89 | 7,170,876 |
| 07/11/25 | 2.50 | 2.67 | 2.49 | 2.66 | 6,594,939 |
| 06/11/25 | 2.76 | 2.78 | 2.4235 | 2.50 | 11,799,535 |
| 05/11/25 | 2.81 | 2.995 | 2.77 | 2.94 | 5,386,632 |
| 04/11/25 | 2.90 | 2.97 | 2.80 | 2.85 | 5,594,826 |
| 03/11/25 | 3.00 | 3.00 | 2.85 | 2.95 | 3,843,376 |
| 31/10/25 | 2.84 | 3.01 | 2.80 | 2.97 | 6,293,389 |
| 30/10/25 | 2.81 | 2.94 | 2.78 | 2.84 | 3,454,115 |
| 29/10/25 | 3.04 | 3.04 | 2.80 | 2.87 | 6,169,701 |
| 28/10/25 | 2.93 | 3.11 | 2.88 | 3.04 | 7,211,749 |
|
|
||||
|
|
||||
|
|